Skip to main content

Doxil Disease Interactions

There are 4 disease interactions with Doxil (doxorubicin liposomal).

Major

Antineoplastics (applies to Doxil) infections

Major Potential Hazard, High plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Methotrexate (methotrexate)." Lederle Laboratories PROD (2002):
  2. "Product Information. Platinol (cisplatin)." Bristol-Myers Squibb PROD (2001):
  3. "Product Information. Vepesid (etoposide)." Bristol-Myers Squibb PROD (2001):
  4. "Product Information. Novantrone (mitoxantrone)." Immunex Corporation PROD (2001):
  5. "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb PROD (2001):
  6. "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb PROD (2001):
  7. "Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation) PROD (2001):
  8. "Product Information. Fludara (fludarabine)." Berlex Laboratories PROD (2001):
  9. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn PROD (2001):
  10. "Product Information. Matulane (procarbazine)." Roche Laboratories PROD (2001):
  11. "Product Information. DTIC-Dome (dacarbazine)." Bayer PROD (2001):
  12. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn PROD (2001):
  13. "Product Information. Leustatin (cladribine)." Ortho Biotech Inc PROD (2001):
  14. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company PROD (2001):
  15. "Product Information. Hycamtin (topotecan)." SmithKline Beecham PROD (2001):
  16. "Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer PROD (2001):
  17. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb PROD (2001):
  18. "Product Information. Nipent (pentostatin)." Hospira Inc PROD (2001):
  19. "Product Information. Tabloid (thioguanine)." Prasco Laboratories PROD (2001):
  20. "Product Information. Xeloda (capecitabine)." Roche Laboratories PROD (2001):
  21. "Product Information. Alkeran (melphalan)." Glaxo Wellcome (2022):
  22. "Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome PROD (2001):
  23. "Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.
  24. "Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc PROD (2001):
  25. "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn PROD (2001):
  26. "Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation PROD (2001):
  27. "Product Information. Jevtana (cabazitaxel)." sanofi-aventis (2010):
  28. "Product Information. Halaven (eribulin)." Eisai Inc (2010):
  29. "Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc. (2021):
View all 29 references
Major

Doxorubicin (applies to Doxil) myelosuppression

Major Potential Hazard, High plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts, Fever

Doxorubicin induces dose-related myelosuppression, primarily affecting leukocytes. Therapy with doxorubicin should be withheld in patients whose bone marrow function is severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy. If the need outweighs the risk, extreme caution should be exercised in administering doxorubicin and the dosage should be reduced. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitory of hematopoietic function is recommended. Doxorubicin is contraindicated in patients with severe persistent drug-induced myelosuppression

References

  1. Johnson PJ, Dobbs N, Kalayci C, Aldous MC, Harper P, Metivier EM, Williams R "Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters." Br J Cancer 65 (1992): 751-5
  2. Maral RJ, Jouanne M "Toxicology of daunorubicin in animals and man." Cancer Treat Rep 65 Suppl 4 (1981): 9-18
  3. Doll DC, Weiss RB "Hemolytic anemia associated with antineoplastic agents." Cancer Treat Rep 69 (1985): 777-82
  4. Tan C, Etcubanas E, Wollner N, Rosen G, Gilladoga A, Showel J, Murphy ML, Krakoff IH "Adriamycin--an antitumor antibiotic in the treatment of neoplastic diseases." Cancer 32 (1973): 9-17
  5. Carter SK "Adriamycin-a review." J Natl Cancer Inst 55 (1975): 1265-74
  6. Bick RL, Fekete LF, Wilson WL "Adriamycin and fibrinolysis." Thromb Res 8 (1976): 467-75
  7. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn PROD (2001):
  8. "Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc PROD (2001):
View all 8 references
Major

Doxorubicin liposomal (applies to Doxil) congestive heart failure

Major Potential Hazard, High plausibility.

Precautions and monitoring of patients administered doxorubicin liposomal are the same as those noted for conventional doxorubicin. Doxorubicin can cause myocardial toxicity leading to congestive heart failure. The incidence of drug-induced congestive heart failure in adults is increased when the total cumulative dose of doxorubicin exceeds 550 mg/m2. Patients with preexisting-existing heart disease, prior irradiation, or previous therapy with doxorubicin or related compounds such as daunorubicin, idarubicin or mitoxantrone are at increased risk of cardiotoxicity at a lower cumulative dose. An electrocardiogram, determination of left ventricular ejection fraction, and/or echocardiogram prior to therapy with doxorubicin, at 400 mg/m2 cumulative dose, and periodically thereafter are recommended.

References

  1. "Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc PROD (2001):
Moderate

Doxorubicin liposomal (applies to Doxil) hepatic dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The pharmacokinetics of doxorubicin liposomal has not been adequately evaluated in patients with hepatic impairment. Doxorubicin is eliminated in large part by the liver. Reduce doxorubicin liposomal injection for serum bilirubin of 1.2 mg/dL or higher.

References

  1. "Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc PROD (2001):

Doxil drug interactions

There are 572 drug interactions with Doxil (doxorubicin liposomal).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer